Collateral sensitivity as a strategy against cancer multidrug resistance

Drug Resistance Updates

Volumn 15, Issue 1-2, 2012, Pages 98-105

  Pluchino, Kristen M ^a,b   Hall, Matthew D ^a   Goldsborough, Andrew S ^a   Callaghan, Richard ^b   Gottesman, Michael M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Collateral sensitivity; MDR1 selective; MRP1; Multidrug resistance; P glycoprotein; Verapamil

Indexed keywords

ANTIMYCIN A1; AUSTOCYSTIN D; CHELATING AGENT; DP44MT; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN 1; NSC 73306; OCTOXINOL; ROTENONE; TIOPRONIN; UNCLASSIFIED DRUG; VERAPAMIL;

CANCER CELL; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CELL KILLING; CELL MEMBRANE FLUIDITY; CELL MEMBRANE POTENTIAL; COLLATERAL SENSITIVITY; DRUG ACTIVITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SELECTIVITY; DRUG TREATMENT FAILURE; HUMAN; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW;

EID: 84860671176     PISSN: 13687646     EISSN: 15322084     Source Type: Journal    
DOI: 10.1016/j.drup.2012.03.002     Document Type: Article

References (71)

1. S. Akiyama, A. Fojo, J.A. Hanover, I. Pastan, and M.M. Gottesman Isolation and genetic characterization of human KB cell lines resistant to multiple drugs Somat. Cell Mol. Genet. 11 1985 117 126
2. M.K. al-Shawi, and A.E. Senior Characterization of the adenosine triphosphatase activity of Chinese hamster P-glycoprotein J. Biol. Chem. 268 1993 4197 4206
3. C. Aleman, J.P. Annereau, X.J. Liang, C.O. Cardarelli, B. Taylor, J.J. Yin, A. Aszalos, and M.M. Gottesman P-glycoprotein, expressed in multidrug resistant cells, is not responsible for alterations in membrane fluidity or membrane potential Cancer Res. 63 2003 3084 3091
4. S.V. Ambudkar, S. Dey, C.A. Hrycyna, M. Ramachandra, I. Pastan, and M.M. Gottesman Biochemical, cellular, and pharmacological aspects of the multidrug transporter Annu. Rev. Pharmacol. Toxicol. 39 1999 361 398
5. R. Barattin, T. Perrotton, D. Trompier, D. Lorendeau, A.D. Pietro, M. d'Hardemare Adu, and H. Baubichon-Cortay Iodination of verapamil for a stronger induction of death, through GSH efflux, of cancer cells overexpressing MRP1 Bioorg. Med. Chem. 18 2010 6265 6274
6. N.T. Bech-Hansen, J.E. Till, and V. Ling Pleiotropic phenotype of colchicine-resistant CHO cells: cross-resistance and collateral sensitivity J. Cell. Physiol. 88 1976 23 31
7. S.E. Bell, D.M. Quinn, G.L. Kellett, and J.R. Warr 2-Deoxy-d-glucose preferentially kills multidrug-resistant human KB carcinoma cell lines by apoptosis Br. J. Cancer 78 1998 1464 1470
8. J. Bentley, D.M. Quinn, R.S. Pitman, J.R. Warr, and G.L. Kellett The human KB multidrug-resistant cell line KB-C1 is hypersensitive to inhibitors of glycosylation Cancer Lett. 115 1997 221 227
9. W. Berger, U. Setinek, P. Hollaus, T. Zidek, E. Steiner, L. Elbling, H. Cantonati, J. Attems, A. Gsur, and M. Micksche Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implications J. Cancer Res. Clin. Oncol. 131 2005 355 363
10. R. Brough, J.R. Frankum, S. Costa-Cabral, C.J. Lord, and A. Ashworth Searching for synthetic lethality in cancer Curr. Opin. Genet. Dev. 21 2011 34 41
11. H.J. Broxterman, H.M. Pinedo, C.M. Kuiper, L.C. Kaptein, G.J. Schuurhuis, and J. Lankelma Induction by verapamil of a rapid increase in ATP consumption in multidrug-resistant tumor cells FASEB J. 2 1988 2278 2282
12. R.A. Cairns, I.S. Harris, and T.W. Mak Regulation of cancer cell metabolism Nat. Rev. Cancer 11 2011 85 95
13. A.M. Calcagno, I.W. Kim, C.P. Wu, S. Shukla, and S.V. Ambudkar ABC drug transporters as molecular targets for the prevention of multidrug resistance and drug-drug interactions Curr. Drug Deliv. 4 2007 324 333
14. R. Callaghan, and J.R. Riordan Collateral sensitivity of multidrug resistant cells to narcotic analgesics is due to effects on the plasma membrane Biochim. Biophys. Acta 1236 1995 155 162
15. D.F. Cano-Gauci, and J.R. Riordan Action of calcium antagonists on multidrug resistant cells. Specific cytotoxicity independent of increased cancer drug accumulation Biochem. Pharmacol. 36 1987 2115 2123
16. S.P. Cole, and R.G. Deeley Transport of glutathione and glutathione conjugates by MRP1 Trends Pharmacol. Sci. 27 2006 438 446
17. H. Farmer, N. McCabe, C.J. Lord, A.N. Tutt, D.A. Johnson, T.B. Richardson, M. Santarosa, K.J. Dillon, I. Hickson, C. Knights, N.M. Martin, S.P. Jackson, G.C. Smith, and A. Ashworth Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 434 2005 917 921
18. E. Fox, and S.E. Bates Tariquidar (XR9576): a P-glycoprotein drug efflux pump inhibitor Expert Rev. Anticancer Ther. 7 2007 447 459
19. A. Ganguly, S. Basu, P. Chakraborty, S. Chatterjee, A. Sarkar, M. Chatterjee, and S.K. Choudhuri Targeting mitochondrial cell death pathway to overcome drug resistance with a newly developed iron chelate PLoS One 5 2010 e11253
20. E. Genoux-Bastide, D. Lorendeau, E. Nicolle, S. Yahiaoui, S. Magnard, A. Di Pietro, H. Baubichon-Cortay, and A. Boumendjel Identification of Xanthones as Selective Killers of Cancer Cells Overexpressing the ABC Transporter MRP1 ChemMedChem 6 2011 1478 1484
21. A.S. Goldsborough, M.D. Handley, A.E. Dulcey, K.M. Pluchino, P. Kannan, K.R. Brimacombe, M.D. Hall, G. Griffiths, and M.M. Gottesman Collateral Sensitivity of Multidrug-Resistant Cells to the Orphan Drug Tiopronin J. Med. Chem. 54 2011 4987 4997
22. M.M. Gottesman, S.V. Ambudkar, and D. Xia Structure of a multidrug transporter Nat. Biotechnol. 27 2009 546 547
23. M.M. Gottesman, T. Fojo, and S.E. Bates Multidrug resistance in cancer: role of ATP-dependent transporters Nat. Rev. Cancer 2 2002 48 58
24. M.D. Hall, K.R. Brimacombe, M.S. Varonka, K.M. Pluchino, J.K. Monda, J. Li, M.J. Walsh, M.B. Boxer, T.H. Warren, H.M. Fales, and M.M. Gottesman Synthesis and structure-activity evaluation of isatin-beta-thiosemicarbazones with improved selective activity towards multidrug-resistant cells expressing P-glycoprotein J. Med. Chem. 54 2011 5878 5889
25. M.D. Hall, M.D. Handley, and M.M. Gottesman Is resistance useless? Multidrug resistance and collateral sensitivity Trends Pharmacol. Sci. 30 2009 546 556
26. M.D. Hall, N.K. Salam, J.L. Hellawell, H.M. Fales, C.B. Kensler, J.A. Ludwig, G. Szakacs, D.E. Hibbs, and M.M. Gottesman Synthesis, activity, and pharmacophore development for isatin-beta-thiosemicarbazones with selective activity toward multidrug-resistant cells J. Med. Chem. 52 2009 3191 3204
27. D. Hanahan, and R.A. Weinberg Hallmarks of cancer: the next generation Cell 144 2011 646 674
28. Y.Y. He, J.L. Huang, D.C. Ramirez, and C.F. Chignell Role of reduced glutathione efflux in apoptosis of immortalized human keratinocytes induced by UVA J. Biol. Chem. 278 2003 8058 8064
29. L. Helson Calcium channel blocker enhancement of anticancer drug cytotoxicity - a review Cancer Drug Deliv. 1 1984 353 361
30. P.J. Jansson, C.L. Hawkins, D.B. Lovejoy, and D.R. Richardson The iron complex of Dp44mT is redox-active and induces hydroxyl radical formation: an EPR study J. Inorg. Biochem. 104 2010 1224 1228
31. D. Joly, P. Rieu, A. Mejean, M.F. Gagnadoux, M. Daudon, and P. Jungers Treatment of cystinuria Pediatr. Nephrol. 13 1999 945 950
32. O. Kaplan, J.W. Jaroszewski, R. Clarke, C.R. Fairchild, P. Schoenlein, S. Goldenberg, M.M. Gottesman, and J.S. Cohen The multidrug resistance phenotype: 31P nuclear magnetic resonance characterization and 2-deoxyglucose toxicity Cancer Res. 51 1991 1638 1644
33. O. Kaplan, G. Navon, R.C. Lyon, P.J. Faustino, E.J. Straka, and J.S. Cohen Effects of 2-deoxyglucose on drug-sensitive and drug-resistant human breast cancer cells: toxicity and magnetic resonance spectroscopy studies of metabolism Cancer Res. 50 1990 544 551
34. H. Kappus, and H. Sies Toxic drug effects associated with oxygen metabolism: redox cycling and lipid peroxidation Experientia 37 1981 1233 1241
35. J. Karwatsky, M.C. Lincoln, and E. Georges A mechanism for P-glycoprotein-mediated apoptosis as revealed by verapamil hypersensitivity Biochemistry 42 2003 12163 12173
36. J. Keenan, Y. Liang, and M. Clynes Two-deoxyglucose as an anti-metabolite in human carcinoma cell line RPMI-2650 and drug-resistant variants Anticancer Res. 24 2004 433 440
37. R.J. Kelly, D. Draper, C.C. Chen, R.W. Robey, W.D. Figg, R.L. Piekarz, X. Chen, E.R. Gardner, F.M. Balis, A.M. Venkatesan, S.M. Steinberg, T. Fojo, and S.E. Bates A pharmacodynamic study of docetaxel in combination with the P-glycoprotein antagonist tariquidar (XR9576) in patients with lung, ovarian, and cervical cancer Clin. Cancer Res. 17 2010 569 580
38. W.H. Koppenol, P.L. Bounds, and C.V. Dang Otto Warburg's contributions to current concepts of cancer metabolism Nat. Rev. Cancer 11 2011 325 337
39. T.C. Kuo, P.C. Chiang, C.C. Yu, K. Nakagawa-Goto, K.F. Bastow, K.H. Lee, and J.H. Guh A unique P-glycoprotein interacting agent displays anticancer activity against hepatocellular carcinoma through inhibition of GRP78 and mTOR pathways Biochem. Pharmacol. 81 2011 1136 1144
40. R.M. Laberge, R. Ambadipudi, and E. Georges P-glycoprotein (ABCB1) modulates collateral sensitivity of a multidrug resistant cell line to verapamil Arch. Biochem. Biophys. 491 2009 53 60
41. N.T. Le, and D.R. Richardson Iron chelators with high antiproliferative activity up-regulate the expression of a growth inhibitory and metastasis suppressor gene: a link between iron metabolism and proliferation Blood 104 2004 2967 2975
42. N.T. Le, and D.R. Richardson The role of iron in cell cycle progression and the proliferation of neoplastic cells Biochim. Biophys. Acta 1603 2002 31 46
43. G.D. Leonard, T. Fojo, and S.E. Bates The role of ABC transporters in clinical practice Oncologist 8 2003 411 424
44. D.W. Loe, R.G. Deeley, and S.P. Cole Verapamil stimulates glutathione transport by the 190-kDa multidrug resistance protein 1 (MRP1) J. Pharmacol. Exp. Ther. 293 2000 530 538
45. J.A. Ludwig, G. Szakacs, S.E. Martin, B.F. Chu, C. Cardarelli, Z.E. Sauna, N.J. Caplen, H.M. Fales, S.V. Ambudkar, J.N. Weinstein, and M.M. Gottesman Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer Cancer Res. 66 2006 4808 4815
46. R.C. Lyon, J.S. Cohen, P.J. Faustino, F. Megnin, and C.E. Myers Glucose metabolism in drug-sensitive and drug-resistant human breast cancer cells monitored by magnetic resonance spectroscopy Cancer Res. 48 1988 870 877
47. K.M. Marks, E.S. Park, A. Arefolov, K. Russo, K. Ishihara, J.E. Ring, J. Clardy, A.S. Clarke, and H.E. Pelish The selectivity of austocystin D arises from cell-line-specific drug activation by cytochrome P450 enzymes J. Nat. Prod. 74 2011 567 573
48. C. Muller, J.D. Bailly, F. Goubin, J. Laredo, J.P. Jaffrezou, C. Bordier, and G. Laurent Verapamil decreases P-glycoprotein expression in multidrug-resistant human leukemic cell lines Int. J. Cancer 56 1994 749 754
49. M. Naito, and T. Tsuruo Competitive inhibition by verapamil of ATP-dependent high affinity vincristine binding to the plasma membrane of multidrug-resistant K562 cells without calcium ion involvement Cancer Res. 49 1989 1452 1455
50. K. Nakagawa-Goto, K.F. Bastow, T.H. Chen, S.L. Morris-Natschke, and K.H. Lee Antitumor agents 260. New desmosdumotin B analogues with improved in vitro anticancer activity J. Med. Chem. 51 2008 3297 3303
51. K. Nakagawa-Goto, P.C. Chang, C.Y. Lai, H.Y. Hung, T.H. Chen, P.C. Wu, H. Zhu, A. Sedykh, K.F. Bastow, and K.H. Lee Antitumor agents 280. Multidrug resistance-selective desmosdumotin B analogues J. Med. Chem. 53 2010 6699 6705
52. S. Nobili, I. Landini, T. Mazzei, and E. Mini Overcoming tumor multidrug resistance using drugs able to evade P-glycoprotein or to exploit its expression Med. Res. Rev. 2011 [epub ahead of print]
53. T. Perrotton, D. Trompier, X.B. Chang, A. Di Pietro, and H. Baubichon-Cortay (R)- and (S)-verapamil differentially modulate the multidrug-resistant protein MRP1 J. Biol. Chem. 282 2007 31542 31548
54. L.M. Prisant Verapamil revisited: a transition in novel drug delivery systems and outcomes Heart Dis. 3 2001 55 62
55. R.W. Robey, C. Ierano, Z. Zhan, and S.E. Bates The challenge of exploiting ABCG2 in the clinic Curr. Pharm. Biotechnol. 12 2010 595 608
56. R.W. Robey, O. Polgar, J. Deeken, K.W. To, and S.E. Bates ABCG2: determining its relevance in clinical drug resistance Cancer Metastasis Rev. 26 2007 39 57
57. G. Szakacs, J.P. Annereau, S. Lababidi, U. Shankavaram, A. Arciello, K.J. Bussey, W. Reinhold, Y. Guo, G.D. Kruh, M. Reimers, J.N. Weinstein, and M.M. Gottesman Predicting drug sensitivity and resistance: profiling ABC transporter genes in cancer cells Cancer Cell 6 2004 129 137
58. G. Szakacs, J.K. Paterson, J.A. Ludwig, C. Booth-Genthe, and M.M. Gottesman Targeting multidrug resistance in cancer Nat. Rev. Drug Discov. 5 2006 219 234
59. W. Szybalski, and V. Bryson Genetic studies on microbial cross resistance to toxic agents: I. Cross resistance of Escherichia coli to fifteen antibiotics J. Bacteriol. 64 1952 489 499
60. V.H. Tran, D. Marks, R.K. Duke, M. Bebawy, C.C. Duke, and B.D. Roufogalis Modulation of P-glycoprotein-mediated anticancer drug accumulation, cytotoxicity, and ATPase activity by flavonoid interactions Nutr. Cancer 63 2011 435 443
61. D. Trompier, X.B. Chang, R. Barattin, A. du Moulinet D'Hardemare, A. Di Pietro, and H. Baubichon-Cortay Verapamil and its derivative trigger apoptosis through glutathione extrusion by multidrug resistance protein MRP1 Cancer Res. 64 2004 4950 4956
62. T. Tsuruo, H. Iida, M. Nojiri, S. Tsukagoshi, and Y. Sakurai Circumvention of vincristine and Adriamycin resistance in vitro and in vivo by calcium influx blockers Cancer Res. 43 1983 2905 2910
63. T. Tsuruo, H. Iida, S. Tsukagoshi, and Y. Sakurai Overcoming of vincristine resistance in P388 leukemia in vivo and in vitro through enhanced cytotoxicity of vincristine and vinblastine by verapamil Cancer Res. 41 1981 1967 1972
64. D. Turk, M.D. Hall, B.F. Chu, J.A. Ludwig, H.M. Fales, M.M. Gottesman, and G. Szakacs Identification of compounds selectively killing multidrug-resistant cancer cells Cancer Res. 69 2009 8293 8301
65. J.R. Warr, M. Anderson, and J. Fergusson Properties of verapamil-hypersensitive multidrug-resistant Chinese hamster ovary cells Cancer Res. 48 1988 4477 4483
66. J.R. Warr, F. Brewer, M. Anderson, and J. Fergusson Verapamil hypersensitivity of vincristine resistant Chinese hamster ovary cell lines Cell Biol. Int. Rep. 10 1986 389 399
67. M. Whitnall, J. Howard, P. Ponka, and D.R. Richardson A class of iron chelators with a wide spectrum of potent antitumor activity that overcomes resistance to chemotherapeutics Proc. Natl. Acad. Sci. U. S. A. 103 2006 14901 14906
68. C.P. Wu, S. Shukla, A.M. Calcagno, M.D. Hall, M.M. Gottesman, and S.V. Ambudkar Evidence for dual mode of action of a thiosemicarbazone. NSC73306: a potent substrate of the multidrug resistance linked ABCG2 transporter Mol. Cancer Ther. 6 2007 3287 3296
69. R.H. Xu, H. Pelicano, Y. Zhou, J.S. Carew, L. Feng, K.N. Bhalla, M.J. Keating, and P. Huang Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia Cancer Res. 65 2005 613 621
70. J. Yuan, D.B. Lovejoy, and D.R. Richardson Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment Blood 104 2004 1450 1458
71. S.F. Zhou Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition Xenobiotica 38 2008 802 832